



Innovating for  
affordable healthcare

## Shilpa Medicare Limited

### Corporate & Admin Office :

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,  
Raichur-584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

Dated: 26<sup>th</sup> April, 2021

Corporate Relationship Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
**Mumbai-400 001**

National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
**MUMBAI-400 051**

Dear Sir/Madam,

**Sub:** Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.

**Ref:** Stock Code: NSE: SHILPAMED/BSE-530549

\*\*\*\*\*

### **Shilpa Pharma, Inc. Sues Novartis Pharmaceutical Corporation for Patent Infringement**

Shilpa Pharma, Inc. a U.S operating company of Shilpa Medicare Limited ("Shilpa") filed patent infringement lawsuit against Novartis Pharmaceutical Corporation in the United States District court for the district of Delaware seeking relief for the infringement of the US Patent No. 9,266,816 entitled "Fingolimod Polymorph and Their Processes".

Shilpa is a global brand in manufacturing and supplying of affordable Active Pharmaceutical Ingredients (APIs), generic and innovative Formulations globally in different markets. As a global brand in Active Pharmaceutical Ingredients, generic and Innovative Formulations, Shilpa re-invests a significant portion of its revenue in R&D each year.

Shilpa invest heavily in R&D as we want to provide the patients with the best affordable pharmaceutical solutions, which resulted in more than 466 patent applications worldwide including 70 patent applications of which 30 patents has been granted in United States alone.

Innovation and protection of intellectual property are cornerstone to Shilpa's success. Shilpa respects and protects its intellectual property rights against any third-party infringers. Shilpa has invested significant time and effort to develop its own IP related to the drug Fingolimod. Shilpa is now making efforts to enforce its IP in the U.S.

This is for your information and records.

With Regards,

For **SHILPA MEDICARE LIMITED**

**V V Krishna Chaitanya**  
Company Secretary & Compliance Officer

